Related Experiment Video

Updated: May 18, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes

Ipsita Pal1, Mahitosh Mandal

  • 1School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur 721302, India.

Acta Pharmacologica Sinica
|September 18, 2012
PubMed

Insights

Targeting the PI3K-Akt pathway is crucial for cancer treatment. Novel second-generation inhibitors show improved selectivity and efficacy, offering new hope for patients with various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Phosphatidylinositol 3-kinase-Akt (PI3K-Akt) pathway regulates cell proliferation and survival.
  • Mutations in the PIK3CA gene enhance PI3K activity, contributing to various cancers like breast, colon, and lung cancer.
  • PI3K pathway deregulation leads to abnormal Akt activity, making it a key target for cancer therapy.

Purpose of the Study:

  • To review current strategies for inhibiting the PI3K-Akt pathway in cancer.
  • To focus on novel therapies, their chemical properties, and clinical development.
  • To explore the efficacy of these inhibitors in both in vitro and in vivo cancer models.

Main Methods:

  • Review of scientific literature on PI3K-Akt pathway inhibitors.
  • Analysis of chemical structures and mechanisms of action of novel inhibitors.
  • Evaluation of preclinical and clinical data for PI3K-Akt targeted therapies.

Main Results:

  • First-generation PI3K-Akt inhibitors showed efficacy but had significant toxic side effects and poor selectivity.
  • Second-generation inhibitors, characterized by specific chemical moieties, exhibit enhanced selectivity and potency.
  • These newer inhibitors demonstrate effectiveness as monotherapies or in combination treatments.

Conclusions:

  • Targeting the PI3K-Akt pathway remains a promising strategy in cancer treatment.
  • Second-generation PI3K-Akt inhibitors represent a significant advancement with improved safety and efficacy profiles.
  • Ongoing research and clinical trials are crucial for realizing the full therapeutic potential of these novel agents.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...